Abstract
We present preliminary results of influenza vaccine effectiveness (VE) in New Zealand using a case test-negative design for 28 April to 31 August 2014. VE adjusted for age and time of admission among all ages against severe acute respiratory illness hospital presentation due to laboratory-confirmed influenza was 54% (95% CI: 19 to 74) and specifically against A(H1N1)pdm09 was 65% (95% CI:33 to 81). For influenza-confirmed primary care visits, VE was 67% (95% CI: 48 to 79) overall and 73% (95% CI: 50 to 85) against A(H1N1)pdm09.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Case-Control Studies
-
Child
-
Child, Preschool
-
Female
-
Hospitalization / statistics & numerical data*
-
Humans
-
Infant
-
Influenza A Virus, H1N1 Subtype / genetics
-
Influenza A Virus, H1N1 Subtype / immunology*
-
Influenza A Virus, H1N1 Subtype / isolation & purification
-
Influenza Vaccines / administration & dosage*
-
Influenza Vaccines / immunology
-
Influenza, Human / immunology
-
Influenza, Human / prevention & control*
-
Influenza, Human / virology
-
Male
-
Middle Aged
-
New Zealand
-
Primary Health Care / statistics & numerical data*
-
Reverse Transcriptase Polymerase Chain Reaction
-
Seasons
-
Sentinel Surveillance
-
Young Adult